Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Corporate Presentation

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Jan 26, 2023 8:57am

232 Views

Post# 35247308

RE:RE:Re: Corporate Presentation

@Lesalpes29. I agree with you. To digesss, the poster who brought Slide 17 to our attention seems to know his business. However before I add at the end of the month I would like confirmation that Slide 17 does in fact contain that change from the previous presentation. I simply want it verified and am not doubting anyone in this matter. Best.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec